Vertex Pharmaceuticals Incorporated VRTX

On September 22, Truist analyst Danielle Brill identified a “significant positive readthrough” for Maze Therapeutics, Inc. (NASDAQ:MAZE) following positive Phase 2 topline data from Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The data validates APOL1 inhibition in classic APOL1-mediated kidney disease (AMKD), supporting an addressable population of over 100,000 patients. Truist reiterated a Buy rating and $64 target […]

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 46.9% over the past six months, topping the S&P 500 by 25.5 percentage points.

Fresh Coverage Puts Maze Therapeutics in Focus Maze Therapeutics (MAZE) moved higher in pre-market trading on 23 September after CIBC began covering the clinical-stage kidney and metabolic disease specialist, with the share reaction unfolding alongside new kidney data from Vertex Pharmaceuticals. Recent trading has been choppy for Maze Therapeutics, with a 1-day share price return that declined 6.69% following a 7-day share price return up 11.82%. The year-to-date share price return is down...

Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.

Vertex Pharmaceuticals has ridden a powerful five year share price run while pushing deeper into kidney disease, endocrinology and pain treatments, which puts fresh attention on what investors are really paying for its cash flows today. With the stock near recent highs after a series of clinical and commercial updates, the open question is whether the current market price lines up with the cash the business is expected to generate over time. Over the past 5 years, Vertex Pharmaceuticals has...

Maze Therapeutics (NASDAQ:MAZE) shares rose 2. 9% in pre-market trading after CIBC initiated coverage of the clinical-stage biopharmaceutical company with an Outperformer rating and a $50 price target.

CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would embarrass the broader market, but the numbers tell a complicated story.

Boost ROI via rare-disease R&D, CRISPR therapies, scalable manufacturing, CDMO partnerships and regulatory incentives that accelerate approvals and commercialization. Autologous Hematopoietic Stem Cell Gene Therapy Market Autologous Hematopoietic Stem Cell Gene Therapy Market Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. Autologous Hematopoietic Stem Cell Gene Therapy Mar

Vertex stock popped Tuesday — while shares of rival Maze Therapeutics skyrocketed — on a surprise expansion for their kidney disease drugs.

Vertex on Tuesday announced results from the mid-stage trial of its experimental pill, inaxaplin, in two groups of patients with APOL1-mediated kidney disease.

Maze Therapeutics stock jumped after Vertex Pharmaceuticals reported positive results for inaxaplin, boosting confidence in a rival treatment from Maze.

CKD drug development is shifting toward disease-modifying and cardiorenal therapies, creating opportunities in early detection, high-risk screening, combinations and licensingDublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Chronic Kidney Disease - Competitive Landscape and Clinical Trial Analysis, 2026" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive assessment of more than 90 companies and over 100 marketed and investigational drugs within the global chronic